Ticker Details
Kala Pharmaceuticals, Inc. Kala Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary nanoparticle-based Mucus Penetrating Particles technology, with focus on the treatment of eye diseases.
IPO Date:	July 20, 2017
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$25.84M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.33 | 4.43%
Avg Daily Range (30 D):	$0.18 | 7.54%
Avg Daily Range (90 D):	$0.11 | 7.40%

Institutional Daily Volume
Avg Daily Volume:	.05M
Avg Daily Volume (30 D):	.13M
Avg Daily Volume (90 D):	.16M

Trade Size
Avg Trade Size (Sh.):	11
Avg Trade Size (Sh.) (30 D):	100
Avg Trade Size (Sh.) (90 D):	21

Institutional Trades
Total Institutional Trades:	197
Avg Institutional Trade:	$1.53M
Avg Institutional Trade (30 D):	$1.04M
Avg Institutional Trade (90 D):	$1.04M
Avg Institutional Trade Volume:	M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.38M
Avg Closing Trade (30 D):	$1.51M
Avg Closing Trade (90 D):	$1.51M
Avg Closing Volume:	7.61K

News

Dec 5, 2025 @ 7:36 PM KALA BIO Announces Closing of $10 Million Register... Source: David Lazar

Sep 29, 2025 @ 5:14 PM Crude Oil Falls Sharply; Carnival Posts Upbeat Ear... Source: Avi Kapoor

Sep 29, 2025 @ 5:06 PM 12 Health Care Stocks Moving In Monday's Intraday ... Source: Benzinga Staff Writer

Sep 29, 2025 @ 2:11 PM Nasdaq Jumps 150 Points; US Pending Home Sales Ris... Source: Avi Kapoor

Aug 8, 2025 @ 12:18 PM Kala Bio (KALA) Q2 Loss Widens 15% Source: Jesterai

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-2.06	$-.14	$.86
Diluted EPS	$-2.06	$-.14	$.86
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-19.65M	$-1.62M	$.69M
Operating Income / Loss	$-30.29M	$-1.8M	$-10.23M
Cost of Revenue
Net Cash Flow	$-46.74M	$-5.79M	$-13.54M
PE Ratio

Splits
May 11, 2026	1:50
Oct 21, 2022	1:50
Aug 26, 2022	1.00:1